Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Matsui venture capital bill (HR 420) endorsed by BIO in House testimony.

Executive Summary

HR 420 VENTURE CAPITAL INCENTIVES SUPPORTED BY BIO in testimony delivered by Connective Therapeutics CEO Tom Wiggans during a March 19 hearing of the House Ways & Means Committee on the Clinton Administration's FY 1998 budget request. Wiggans endorsed House legislation (HR 420) introduced by Reps. Matsui (D-Calif.), English (R-Penn.) and McCrery (R-La.). The Matsui bill is a reprise of legislation introduced during the 104th Congress ("The Pink Sheet" June 26, 1995, T&G-3).



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts